Suze Orman Warned 390,000 People Their Medicare Plans Are Shutting Down, Then CNBC Called the Same Stock a Turnaround

Published October 7, 2026, 1:42pm ET · 4 min read

Money Talks desk. Editor: Jake FitzGerald.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Suze Orman with short blonde hair in a blue leather jacket speaking into a microphone and gesturing with her raised hand
© Suze Orman

On October 4, Suze Orman, the personal finance author and former CNBC host, had a warning for her podcast listeners covered by UnitedHealth Group (NYSE:UNH | UNH Price Prediction): “If you have UnitedHealth Group, about 390,000 people are part of plans that are shutting down.” A UnitedHealth spokesperson later confirmed that figure to Bloomberg. Orman also said Humana (NYSE:HUM) will cut plans covering about 600,000 people. She added that CVS Health (NYSE:CVS), through Aetna, and Centene (NYSE:CNC) are also reducing their Medicare Advantage offerings. Centene’s Wellcare unit is exiting Hawaii, Oklahoma, and Tennessee entirely for 2027, though it is retaining Special Needs Plans in Nevada and Ohio.

Two days after Orman’s warning, Kevin Simpson made UnitedHealth his final trade on CNBC’s Halftime Report: “UNH has a turnaround story. And the fundamentals are starting to improve.”

Plan Exits Repair Margins and Cost Members Their Coverage

Orman and Simpson are describing the same event from two different vantage points. When UnitedHealth reported third-quarter 2026 results on October 13, the numbers backed the turnaround argument. The medical care ratio, which measures the share of premiums spent on care, improved to 88.4% from 89.9% a year earlier. Adjusted earnings per share came in at $4.69, well above analyst estimates of around $4.14, and management raised its full-year 2026 guidance to at least $20.50 per share. The company also confirmed that Medicare Advantage membership has contracted by 935,000 since year-end 2025. That shrinkage is a feature, not a flaw, in the turnaround thesis: UnitedHealth is shedding lower-margin plans to stabilize profitability.

The stock now trades near $404, up roughly 25% year-to-date and well above the $376 level it held when Orman made her warning. For members, the date that matters most is not an earnings call but December 7.

UNH earnings explorer

Orman Is Right, and the Exit Hands Members a Rare Advantage

Orman is right to sound the alarm, but her warning stops short of the most useful part. Nobody here ends up uninsured. If you do nothing, you go back to Original Medicare on January 1, without Part D drug coverage. The bigger risk is picking another Medicare Advantage plan in a rush and giving up a right you may never get back.

A discontinued plan triggers a guaranteed-issue right to certain Medigap policies. During that window, an insurer cannot deny your application or charge you more based on your health history. Outside protected windows, most states allow Medigap insurers to review your medical history and decline your application. You can act during Open Enrollment, running October 15 through December 7, or during a special enrollment period that lasts for two months after the plan’s contract ends. UnitedHealthcare has also confirmed that members who do not actively choose a replacement will automatically revert to Original Medicare, with a special election period running through February 28, 2027, to select a new Medicare Advantage plan.

Medigap matters because Original Medicare carries no annual spending cap. In 2026, a single hospital stay triggers a $1,736 Part A deductible per benefit period. Skilled nursing facility days 21 through 100 cost $217 per day. A Medigap policy covers most of those gaps and lifts the ceiling on your annual exposure.

Your Medical History Decides Which Path Costs Less

The comparison between Medicare Advantage and Medigap comes down to your own health history. Consider a replacement Medicare Advantage plan with a $0 premium and a $6,000 out-of-pocket maximum, against a Medigap Plan G policy at $200 a month, or $2,400 a year.

If you’re healthy and spend about $800 a year on copays, Medicare Advantage wins the math exercise easily.

A chronic condition changes the calculation. With heart failure, cancer treatment, or dialysis, you can hit the out-of-pocket maximum every year. Over five years, that totals $30,000 in Advantage cost-sharing. After accounting for Medigap premiums over the same period, the gap in Medigap’s favor reaches roughly $18,000. Medigap also allows you to see any doctor nationwide who accepts Medicare, with no network restrictions to navigate.

Healthy readers face a timing problem that the math misses. Choosing another Advantage plan today and receiving a serious diagnosis in 2029 could leave a Medigap insurer free to turn you down. The guaranteed-issue window functions like insurance on your future health, and once it closes, it does not reopen.

Four Steps to Take Before December 7

  1. Find your termination letter. Check your Annual Notice of Change or nonrenewal notice to confirm your plan is ending. Keep the letter, because Medigap insurers may ask for it as proof of your guaranteed-issue right.
  2. Run Medicare.gov’s Plan Finder. Enter every prescription and every doctor. Compare each plan’s out-of-pocket maximum against what you actually spent this year.
  3. Get Medigap quotes in your ZIP code now. Ask insurers which plans they sell under guaranteed issue in your state, and apply before the window closes.
  4. Add a standalone Part D plan. If you choose Original Medicare plus Medigap, enroll in drug coverage at the same time. That avoids a gap in drug coverage and late-enrollment penalties.

A plan closing opens a short window to buy Medigap regardless of your health, and the decision is due by December 7.

Editor’s note: This update corrects the article’s statement that UnitedHealth had not confirmed the 390,000-member figure (a spokesperson confirmed it to Bloomberg) and replaces the Q2 2026 medical care ratio with the Q3 2026 figure of 88.4%, reported on October 13. The stock price has been updated from approximately $376 to roughly $404, reflecting its year-to-date gain of about 25%. Details on Centene’s specific state exits for 2027 and UnitedHealth’s raised full-year adjusted EPS guidance of at least $20.50 have also been added.

Contact [email protected] for any questions or corrections.

Jake FitzGerald

Jake has been been working in financial media for almost 15 years. He focuses on all things personal finance for 24/7 Wall St. with high hopes to educate and entertain. Most recently, Jake spent 12 years working various roles at The Motley Fool. He started copy editing fool.com content, worked on premium and marketing campaigns, and helped launch The Ascent, a personal finance brand.

His work has been featured on platforms like MSN, Yahoo Finance, USA Today, and more. He's written about credit cards, social security, ETFs, savings accounts, and just about anything else you can imagine when thinking about money. Jake love to cook, play golf, and tell people he's never had a cavity. (It's true!)

All articles →